Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to discontinue development of its lead clinical assets AXN-2510 and AXN-27M and to terminate its partnership with ImmuneOnco.
Analysts at Baird downgraded the stock to ‘Neutral’ on the update. The firm cut its price target to $7 from $180, roughly in line with Instil’s cash value.
The analysts expressed disappointment given earlier optimism around AXN-2510 and the broader PD-(L)1xVEGF class. “We’re disappointed by this news given the early encouraging data from AXN-2510 and our enthusiasm for the PD-(L)1xVEGF class,” the analysts wrote.
While management did not disclose detailed reasons for discontinuing the programs, Baird wrote that it suspects the decision was informed by evolving clinical data. The firm added that although early results appeared broadly in line with peers, “it appears further clinical study results did not materialize in the way we had hoped they would.”
Baird noted that AXN-2510 had been viewed as Instil’s primary value driver and a potential fast follower in the PD-(L)1xVEGF space. With the program now shelved and a limited remaining pipeline, the firm sees fewer near-term catalysts.
Looking ahead, the analysts expect management to explore new business development opportunities but highlighted balance-sheet constraints, noting approximately $83.4 million in cash at the end of the third quarter of 2025 and an estimated quarterly burn of about $20 million.